The insider ownership percentage is the key indicator, can be used by investors, to measure the outlook of senior management has on their company. Insider ownership for the NBIX is 0.90%.
Insider trading is the buying or selling of any publicly traded company’s stock and this can be done by someone who has non-public, material information about that NBIX. Insider trading can be illegal or legal depending on when the insider makes the trade. It is illegal when the material information is still non-public. The insider transactions of the company (6-month change in insider ownerships) for the Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is -19.22%.
Institutional transactions is the amount of a Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s available stock owned by mutual or pension funds, insurance companies, investment firms, private foundations, endowments or other large entities that actually manage the funds on the behalf of others, so its an interesting element for the traders to note it, and the Institutional ownership for the NBIX is -1.08%.
A Healthcare sector firm, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock gained 0.22% on Wednesday and when day-trade ended the stock finally concluded at $87.12 and number of shares that changed hands during the day are 512369. The number of shares NBIX stock currently held by all its shareholders are 91.06 and floated shares, the number of shares are available for trading in an open market on last trading day are 90.13. The average volume of shares for 3 months is 844.93 and NBIX stock value has moved between $64.53 – 126.26 in last one year.
The Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s latest earnings date is 7/29/2019. The Gross margin is the difference between the revenue and the cost of goods sold (COGS), divided by revenue. In other words, Gross Margin is a percentage value, while Gross Profit is a monetary value. The valuable gross margin for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is 99.00% and the profit margin is -7.60% and the stock has gained 22.00% in 2019 to date.
[finviz ticker=NBIX]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s monthly stock performance is 6.17%, the quarterly performance is -2.45%, the half year performance is calculated as 3.20%. The yearly performance of NBIX is -15.26%.
The higher the volatility, the riskier the security. For example, when the stock market rises and falls more than one percent over a sustained period of time, it is called a “volatile” market, if the stock price stays relatively stable, the security has low volatility. The Neurocrine Biosciences, Inc. (NASDAQ:NBIX) weekly volatility is measured as 3.00% and monthly volatility measured as 2.92%.
Return on assets (ROA) is a main indicator of how profitable a company is relative to its total assets. NBIX return on assets is -4.20%, the return on equity (ROE) of the Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is -9.10%, while the most important return on investment is calculates as a percentage and is typically used for personal financial decisions, and NBIX return on investment is 4.20%.
The price to sales ratio is 15.30, and price to book ratio is 19.40, price to cash per share ration is 15.14, price to free cash flow is 19832.00.
Analysts mean target price for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is $105.38 while analysts mean recommendation is 1.80. The current share price indicates that stock is -31.39% away from its one year high and is moving 34.61% ahead of its 52-week low. NBIX’s distance from 20 day simple moving average is 3.44% and distance from 50-Day simple moving average is 7.13%.
